Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 73
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
U.S. Stocks: Nasdaq Futures Up After Apple, Home Sales Loom
Upbeat Apple results were calling the shots on Tuesday for U.S. stock futures and pushing ahead Nasdaq-100 futures in what otherwise looked like a low-key start.
Top Equities Stories Of The Day
European Stock Markets Edge Higher
FTSE 100 Climbs As Oil Stocks Advance
Verizon Results to Show Competitive Impact -- Earnings Preview
Wells Fargo Third-Quarter Profit Rises -- 5th Update
Stifel Financial to Hire Two Former Merrill Lynch Advisers
Qualcomm Pounces On U.K. Chip Maker
U.S. Stocks Gain, but IBM Weighs on Dow
U.S. Stocks Rebound After Recent Losses
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 183045 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist